If you’ve been watching NZX-listed stocks lately, you’ve probably noticed Ryman Healthcare’s share price — it’s been a rough ride. Once a market darling trading at NZ$4.80 in 2021, the retirement village operator now sits at NZ$2.25, a 55% drop that has investors asking hard questions about debt, dividends, and the future of New Zealand’s aged care sector. This article cuts through the noise with the latest data, analyst views, and what it all means for your portfolio.

Don't miss these

4 related posts

Current share price (NZX:RYM): NZ$2.25 (as of July 2026) ·
52-week high: NZ$4.80 (2025) ·
52-week low: NZ$2.14 (2026) ·
Market cap: approximately NZ$1.5 billion ·
Dividend yield: approx. 3.5% (prior to 2024 cuts)

Quick snapshot

1Current Price Snapshot
2Key Risks
  • Debt of NZ$1.8 billion (NZX announcement (official filing))
  • Dividend cut from 8.0c to 4.5c (NZX announcement (official filing))
  • Occupancy rate at 88% (NZX announcement (official filing))
3Analyst Consensus
  • 10 out of 15 analysts rate it Hold
  • Average price target NZ$2.80
  • Bear case: NZ$2.00
4Dividend Status
  • Last paid Oct 2025: 4.5c/share
  • DRP active with 2.5% discount
  • Likely suspension in FY2027

Ten key facts, one pattern: almost every metric points to a company in transition — shedding debt, shrinking dividends, and betting on a turnaround.

Label Value
Company Ryman Healthcare Limited
Ticker RYM.NZ (NZX) / RYHTY (OTC)
Sector Healthcare / Retirement Villages
Current price (July 2026) NZ$2.25
52-week high NZ$4.80
52-week low NZ$2.14
Market cap NZ$1.5 billion
Net debt NZ$1.8 billion
Dividend yield (trailing) 3.5%
Occupancy rate 88%
The paradox

Ryman’s share price has been cut in half, yet its net tangible assets (NTA) of NZ$4.005 per share — according to NZX instrument page (official market data) — suggest the stock trades at a 44% discount to book value. That’s either a value trap or a once-in-a-decade opportunity, depending on whether the debt overhaul works.

What is happening with Ryman Healthcare?

Share price decline and recent performance

  • Ryman Healthcare share price fell from NZ$4.80 (2025 high) to NZ$2.14 (2026 low), a 55% decline (NZX instrument page (official market data)).
  • First-half 2026 earnings showed net profit down 40% year-on-year (Ryman Healthcare company investor news).
  • Company cited rising construction costs and regulatory changes in the aged care sector as headwinds.
What to watch

Ryman’s own guidance for FY26 ORA sales of 1,300–1,400 units, up from 1,100–1,300, signals that management believes the demand is there — but the market is pricing in a recovery that hasn’t materialised yet.

The implication: the share price narrative is now tied directly to execution, not just balance-sheet fixes.

Key operational updates

  • In November 2025, Ryman completed a full refinancing of its NZ$2.0 billion syndicated loan facilities, extending the average tenor to five years (Ryman Healthcare company investor news).
  • The refinancing introduced a new structure that better aligns with its operating model and improved financial covenants (NZX announcement (official filing)).
  • Net debt was reduced by NZ$94 million to NZ$1.57 billion in H2 2026, with free cash flow improving by NZ$282.5 million to NZ$188.3 million (Quartr earnings summary platform).

The implication: the company is making progress on its debt profile, but the market is waiting for proof that operational improvements will follow.

Why is the Ryman share price dropping?

Debt and capital structure concerns

  • Net debt stood at NZ$1.8 billion as of March 2026, with a debt